Furthermore, due to the lack of original data, we were unable to perform subgroup analysis based on more PD-L1 cut-off values (5%, 10% and 20%), other molecular markers (ROS, ALK, or tumour mutation burden), and clinical stages to identify the specific population that stands to benefit from this treatment. This evidence concerns the gene ALK and neoplasm.